By Providence Ayanfeoluwa

Tuberculosis, TB remains one of Nigeria’s most urgent public health challenges, despite years of effort, the country continues to carry a heavy disease burden, straining patients, healthcare workers, and national systems.

According to Network Head, Anglo-West Africa, Roche Diagnostics, Roberto Taboada, yet, progress is undeniable. In 2020 alone, Nigeria reported a 15 percent increase in TB case detection—a milestone that reflects stronger screening and expanded case-finding efforts. The question now is how to accelerate this momentum.

The answer lies in diagnostics. Traditional, siloed approaches to disease testing are giving way to integrated systems that maximize efficiency.

Instead of duplicating infrastructure for each condition, modern laboratory medicine enables one sample to deliver results for multiple diseases.

This is especially critical in Nigeria, where comorbidities such as HIV compound the TB burden.

Integration not only reduces inefficiencies but also strengthens healthcare resilience. By leveraging existing networks, Nigeria can scale testing capacity, confirm cases faster, and improve outcomes across multiple disease areas. The World Health Organization has emphasized this shift, underscoring the importance of high-throughput, cost-effective diagnostics in resource-constrained settings.

Encouragingly, Nigerian policymakers are embracing this vision. With tighter global funding, efficiency has become a priority. Public-private collaboration is driving scalable solutions aligned with national TB programme goals—solutions that promise higher testing volumes, smarter use of infrastructure, and sustainable impact.

As Nigeria marks World TB Day, the nation stands at a turning point. Strengthening TB diagnostics is no longer just about expanding access; it’s about building a system that is integrated, efficient, and future-ready.

If this trajectory continues, Nigeria could transform TB from a pressing headline into a conquered chapter of history—well before the WHO’s 2030 targets.